These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 6123462)

  • 21. Adenosine, adenosine A 2A antagonists, and Parkinson's disease.
    Jenner P; Mori A; Hauser R; Morelli M; Fredholm BB; Chen JF
    Parkinsonism Relat Disord; 2009 Jul; 15(6):406-13. PubMed ID: 19446490
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Dopamine-receptor stimulants in the treatment of Parkinson's disease (author's transl)].
    Ringwald E; Hirt D; Markstein R; Vigouret JM
    Nervenarzt; 1982 Feb; 53(2):67-71. PubMed ID: 7063089
    [No Abstract]   [Full Text] [Related]  

  • 23. [Cholinergic and dopaminergic mechanisms in Huntingtons' chorea].
    Aquilonius SM; Sjöström R
    Nord Med; 1971 May; 85(21):675. PubMed ID: 4325716
    [No Abstract]   [Full Text] [Related]  

  • 24. Dopamine-modulating drugs, amenorrhea-galactorrhea and neuropsychiatric illnesses.
    Frye PE
    W V Med J; 1983 Aug; 79(8):161-4. PubMed ID: 6138902
    [No Abstract]   [Full Text] [Related]  

  • 25. Neurocircuitry of the basal ganglia studied by monitoring neurotransmitter release. Effects of intracerebral and perinatal asphyctic lesions.
    Herrera-Marschitz M; Loidl CF; You ZB; Andersson K; Silveira R; O'Connor WT; Goiny M
    Mol Neurobiol; 1994; 9(1-3):171-82. PubMed ID: 7888094
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [New approaches to analysis of the interrelationship between cholinergic and dopaminergic mediator systems].
    Podosinovikova NP; Kosmachev AB; Tonkopiĭ VD; Zagrebin AO; Evdokimova EA; Maslov AM; Petrov VV; Dolgo-Saburov VB
    Eksp Klin Farmakol; 2001; 64(6):20-2. PubMed ID: 11871230
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neurochemical pathology and pharmacology of brain dopamine and acetylcholine: rational basis for the current drug treatment of Parkinsonism.
    Hornykiewicz O
    Contemp Neurol Ser; 1971; 8():33-65. PubMed ID: 5162181
    [No Abstract]   [Full Text] [Related]  

  • 28. [Etiology of schizophrenia: neurochemical aspects].
    de las Cuevas Castresana C; González de Rivera JL
    Neurologia; 1994 Feb; 9(2):54-9. PubMed ID: 7515627
    [No Abstract]   [Full Text] [Related]  

  • 29. Balance of transmitter activities in the basal ganglia loops.
    Schmidt WJ
    J Neural Transm Suppl; 1995; 46():67-76. PubMed ID: 8821042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Action sites of morphine--effects on dopaminergic and GABA-containing neurons in the basal ganglia].
    Kondo Y
    Osaka Daigaku Shigaku Zasshi; 1980 Jun; 25(1):15-28. PubMed ID: 6256512
    [No Abstract]   [Full Text] [Related]  

  • 31. Histology and histochemistry of the peripheral neural plexus in the Aplysia gill.
    Peretz B; Estes J
    J Neurobiol; 1974; 5(1):3-19. PubMed ID: 4152092
    [No Abstract]   [Full Text] [Related]  

  • 32. Overview of the extranigral aspects of Parkinson disease.
    Lim SY; Fox SH; Lang AE
    Arch Neurol; 2009 Feb; 66(2):167-72. PubMed ID: 19204152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Neuroleptic malignant syndrome-like state in eight patients with parkinsonism].
    Fujitake J; Kuno S; Nishitani H
    Rinsho Shinkeigaku; 1984 Apr; 24(4):371-8. PubMed ID: 6744760
    [No Abstract]   [Full Text] [Related]  

  • 34. [Microdialysis cerebral. Main application of this technique].
    Blanco-Lezcano L; Pavón-Fuentes N; Blanco-Lezcano V
    Rev Neurol; 2001 Sep 1-15; 33(5):464-70. PubMed ID: 11727216
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peculiarities of L: -DOPA treatment of Parkinson's disease.
    Kostrzewa RM; Nowak P; Kostrzewa JP; Kostrzewa RA; Brus R
    Amino Acids; 2005 Mar; 28(2):157-64. PubMed ID: 15750845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Are there clinically significant differences between dopamine agonists.
    Stocchi F; Vacca L; Onofrj M
    Adv Neurol; 2003; 91():259-66. PubMed ID: 12442684
    [No Abstract]   [Full Text] [Related]  

  • 37. [Parkinson disease and the neuronal dopamine uptake complex].
    Costentin J
    Ann Pharm Fr; 1995; 53(4):145-54. PubMed ID: 7574268
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Antiparkinsonian drugs (author's transl)].
    Ando K
    No To Shinkei; 1980 Aug; 32(8):743-53. PubMed ID: 7008813
    [No Abstract]   [Full Text] [Related]  

  • 39. Neurotransmitters and neurodegenerative disorders.
    Kanazawa I
    Clin Ther; 1984; 7 Spec No():48-58. PubMed ID: 6152198
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Physiopathology of schizophrenia. Some biologic aspects].
    Tissot R
    Schweiz Arch Neurol Neurochir Psychiatr; 1984; 135(1):29-40. PubMed ID: 6148787
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.